+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Anorexia - Epidemiology forecast - 2030

  • ID: 5307001
  • Report
  • March 2021
  • Region: Global
  • 100 pages
  • DelveInsight

This ‘Cancer Anorexia - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the cancer anorexia, historical and forecasted epidemiology as well as the cancer anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Cancer Anorexia Disease Understanding

Cancer Anorexia Overview

Cancer is the second leading cause of death worldwide. Toward the end of life, individuals with cancer experience a substantial symptom burden. The top three common symptoms in patients with cancer at the end of life are fatigue, pain, and anorexia (appetite loss). Anorexia is the lack or loss of appetite or desire to eat leading to reduced intake; associated with metabolic derangements, including the release of proinflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha produced by the immune system and tumor cells. It is the most common cause of decreased nutrient intake that triggers malnutrition and muscle wasting.

The causes of anorexia can be characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis and an increase in protein degradation, or a combination of both. There are numerous causes, which can be conveniently categorized as being due to central or peripheral mechanisms. Peripheral causes can be directly due to tumors causing dysphagia or directly impinging on gastrointestinal function; tumor producing substances that alter food intake, e.g., lactate, tryptophan, or parathormone-related peptide; tumors leading to alterations in nutrients resulting in the condition, e.g., zinc; or tumors producing inflammation leading to cytokine release. On the other hand, central causes of anorexia can be depression, pain, or various alterations in central neurotransmitters.

The anorexia and accompanying weight loss may occur at any stage of illness with variable severity, and it may be related to several causal factors. Symptoms that interfere with food intake include early satiety taste alterations, smell alterations, meat aversion, and nausea/vomiting. Thus, it contributes to the development of malnutrition and cachexia since it reduces the oral intake of calories, thus promoting skeletal muscle wasting. This effect is more dramatic than in simple starvation because energy expenditure is often increased.

In general, the condition's presence is clinically diagnosed when cancer patients refer to any negative change of their appetite. However, more symptoms such as reduction of appetite, early satiety, changes in taste, changes in odor, depression, dysphagia, painful swallowing, assessment of meal size, assessment of taste and odor are essential to diagnose the condition. Cancer anorexia is a syndrome that can be effectively treated. However, it is unknown whether its amelioration and improvements in energy intake would result in a long-term benefit for patients with cancer in terms of reduced morbidity and mortality.

Cancer Anorexia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence Cases of Anorexia by Cancer Types in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Key Findings

This section provides glimpse of the Cancer Anorexia epidemiology in the 7MM.

  • The total incident cases of anorexia by cancer types in the seven major markets was estimated to be 740,055 in 2020.
  • The total incident cases of anorexia by cancer types in the 7 MM is expected to increase at a CAGR of 1.1% during the forecast period 2021-2030.
  • In the United States, the incidence population of anorexia by cancer types was 265,539 in 2020.
  • In 2020, the incident cases of cancer anorexia in advanced cancers, namely, colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer, and liver cancer in the US were 41,812, 140,931, 31,260, 13,416, 16,268 and 21,852, respectively.
  • In the EU5 countries, the incident population of anorexia by cancer types was maximum in Germany with 72,040 cases, followed by the France with 58,419 cases in 2020. While, Spain accounted for the lowest incident population of the indication with 36,474 cases in 2020.
  • As per this analysis, Japan had 197,803 incident cases of anorexia by cancer types in 2020.

Country Wise- Cancer Anorexia Epidemiology

The epidemiology segment also provides the Cancer Anorexia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Scope of the Report

  • The report covers the descriptive overview of Cancer Anorexia, explaining explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cancer Anorexia.

Report Highlights

  • Ten Year Forecast of Cancer Anorexia
  • 7MM Coverage
  • The publisher has analysed incident population of cancer anorexia in the 7MM which suggests that the patient pool will increase during the forecast period of 2021-2030.

Analyst Comments

  • Cancer anorexia is one of the most prevalent and troublesome clinical problems experienced by patients with cancer during and after therapy. It is a phenomenon that comes on in patients with cancer, very frequently when they have advanced cancer such as pancreatic and lung cancer and less frequent in patients with cancers of the breast.
  • There is a data crunch in the EU5 and Japan as not many studies have been conducted in these regions which have mentioned the incidence of cancer anorexia, CC, or CACS. In the US, some studies are available; however, the studies are quoting numbers from previously conducted systematic or review studies, and not many recent studies are available. From the studies included in the scope of this report, it can be deduced that cancer anorexia is highly incident in cancer patients, especially in highly progressive cancers.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Cancer Anorexia?
  • What is the historical Cancer Anorexia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Cancer Anorexia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cancer Anorexia?
  • Out of the above-mentioned countries, which country would have the highest incident population of Cancer Anorexia during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Reasons to Buy

The cancer anorexia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM cancer anorexia market.
  • Quantify patient share distribution in the 7MM for cancer anorexia.
  • The cancer anorexia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Cancer Anorexia epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Note: Product cover images may vary from those shown
1 Key Insights

2 Cancer Anorexia Market Overview at a Glance
2.1 Patient Share (%) Distribution of Cancer Anorexia in 2018
2.2 Patient Share (%) Distribution of Cancer Anorexia in 2030

3 Executive Summary of Cancer Anorexia

4 Disease Background and Overview: Cancer Anorexia
4.1 Introduction
4.2 Pathogenesis
4.3 Pathophysiology
4.4 Risk factors and assessment
4.5 Diagnosis

5 Epidemiology and Patient Population
5.1 Key Findings
5.2 7MM Total Incidence of Anorexia by cancer types

6 Country-wise Epidemiology of Cancer Anorexia
6.1 Assumptions and Rationale
6.2 The United States
6.2.1 Incidence of Anorexia by cancer types in the US
6.3 EU5 Countries
6.3.1 Germany
6.3.1.1 Incidence of Anorexia by cancer types in Germany
6.3.2 France
6.3.2.1 Incidence of Anorexia by cancer types in France
6.3.3 Italy
6.3.3.1 Incidence of Anorexia by cancer types in Italy
6.3.4 Spain
6.3.4.1 Incidence of Anorexia by cancer types in Spain
6.3.5 United Kingdom
6.3.5.1 Incidence of Anorexia by cancer types in the UK
6.4 Japan
6.4.1 Incidence of Anorexia by cancer types in Japan

7 Recognized Establishments

8 Appendix
8.1 Bibliography
8.2 Report Methodology

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1: Summary of Cancer Anorexia, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Types of anorexia in cancer
Table 3: Characteristics of starvation response versus cancer anorexia syndrome
Table 4: Total Incidence of Anorexia by cancer types in the 7MM (2018-2030)
Table 5: Incidence of Anorexia by cancer types in the United States (2018-2030)
Table 6: Incidence of Anorexia by cancer types in Germany (2018-2030)
Table 7: Incidence of Anorexia by cancer types in France (2018-2030)
Table 8: Incidence of Anorexia by cancer types in Italy (2018-2030)
Table 9: Incidence of Anorexia by cancer types in Spain (2018-2030)
Table 10: Incidence of Anorexia by cancer types in the United Kingdom (2018-2030)
Table 11: Incidence of Anorexia by cancer types in Japan (2018-2030)

List of Figures
Figure 1: Mechanisms of Anorexia in Cancer
Figure 2: Total Incidence of Anorexia by cancer types in the 7MM (2018-2030)
Figure 3: Incidence of Anorexia by cancer types in the United States (2018-2030)
Figure 4: Incidence of Anorexia by cancer types in Germany (2018-2030)
Figure 5: Incidence of Anorexia by cancer types in France (2018-2030)
Figure 6: Incidence of Anorexia by cancer types in Italy (2018-2030)
Figure 7: Incidence of Anorexia by cancer types in Spain (2018-2030)
Figure 8: Incidence of Anorexia by cancer types in the United Kingdom (2018-2030)
Figure 9: Incidence of Anorexia by cancer types in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll